Tuberculosis in persons with human immunodeficiency virus infection: Clinical and public health aspects

Seminars in Respiratory and Critical Care Medicine

Volumn 18, Issue 5, 1997, Pages 471-484

  Hopewell, Philip C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Human immunodeficiency virus; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PENTAMIDINE; PLACEBO; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REVIEW; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0031454654     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009362     Document Type: Review

References (78)

1. Markowitz N, Hansen N, Hopewell PC et al. Incidence of tuberculosis in the United States among HIV infected patients. Ann Intern Med 1997;126:123-132
2. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Grit Care Med 1995;151:129-135
3. Selwyn PA, Hartel D, Lewis VA et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550
4. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV infected drug users with cutaneous anergy. JAMA 1992;268:504-509
5. Allen S, Batungwanayo J, Kerlikowski K, et al. Prevalence of tuberculosis in HIV infected urban Rwandan women. Am Rev Respir Dis 1992;146:1439-1444
6. Antonucci G, Girardi E, Raviglione MC, Ippolito G, GISTA. Risk factors for tuberculosis in HIV infected persons: A prospective cohort study. JAMA 1995;274:143-148
7. Graham NMH, Nelson KE, Solomon L et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and - seronegative intravenous drug users. JAMA 1992;267:369-373
8. Sudre P, Hirschel BJ, Gatell JM et al. Tuberculosis among European patients with the acquired immuned deficiency syndrome. Tuberc Lung Dis 1996;77:322-328
9. Onorato IM, McCray E, Field Services Branch. Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States. J Infect Dis 1992;165:87-92
10. Onorato I, McCombs S, Morgan WM, McCray E. HIV infection in patients attending tuberculosis (TB) clinics, United States, 1988-1991. Presented at the Ninth International Conference on AIDS; Julv 1993; Berlin (Abstract no. WS-C18-6, p. 99)
11. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 1995. August 1996
12. Tuberculosis Control Division, City and County of San Francisco. Tuberculosis in San Francisco, 1996. March 1997
13. Gilks CF, Brindle RJ, Otieno LS. Extrapulmonary and disseminated tuberculosis in HIV seropositive patients presenting to the acute medical services in Nairobi. AIDS 1990;4:981-985
14. Nunn P, Gicheka R, Hages S et al. Cross-sectional survey of HIV infection among patients with tuberculosis in Nairobi, Keyna. Tuberc Lung Dis 1992;73:45-51
15. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: Clinical features, diagnosis, and treatment Bull World Health Organ 1992;70:515-526
16. Long R, Scalcini M, Manfreda J et al. Impact of human immunodeficiency virus type 1 on tuberculosis in rural Haiti. Am Rev Respir Dis 1991;143.69-73
17. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994;72:213-220
18. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-226
19. De Cock KM, Soro B, Coulibaly IM, Lucas SB. Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 1992;268:1581-1587
20. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982;125:8-15
21. Daniel TM, EllnerJJ. Immunology of tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. New York: Marcel Dekker, Inc.; 1993:75-101
22. Nardell E, McInnis B, Thomas B, Weidhaus S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986;315:1570-1575
23. Small PM, Shafer RW, Hopewell PC et al. Exogenous reinfection with multidrug-resistant Mycobactenum tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-1144
24. Daley CL, Small PM, Ponce de León A et al. Tuberculosis recurrences in San Francisco: Relapse or reinfection. Am J Respir Crit Care Med 1996;153 (part 2):A410
25. Daley CL, Small PM, Schecter GF et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus: An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-235
26. DiPern G, Danzi MC, DeChecci G et al. Nosocomial epidemic of active tuberculosis among HIV infected patients. Lancet 1989;2:1502-1504
27. Theuer CP, Hopewell PC, Elias D, Schecter GF, Rutherford GS, Chaisson RE. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990;162:8-12
28. Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993;148:1292-1297
29. Markowitz N, Hansen NI, Wilcosky TC et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993;119:185-193
30. Chin DP, Osmond D, Page-Shafer K et al. Reliability of anergy skin testing in persons with HIV infection. Am J Respir Crit Care Med 1996;153-1982-1984
31. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1992;146:1623-1633
32. Batungwanayo J, Taelman H, Dhote R, Bogaerts J, Allen S, Van De Perre P. Pulmonary tuberculosis in Kigali, Rwanda: Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992;146:53-56
33. Hopewell PC. Tuberculosis and infection with the human immunodeficiency virus. In: Reichman LB, Hershfield ES, eds Tuberculosis: A Comprehensive International Approach. New York: Marcel Dekker Inc; 1993:369-394
34. Chaisson RE, Schecter GF, Theuer CP, Rutherford SW, Echenberg DF, Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 1987;136:570-574
35. Pitchenik AE, Rubinson HA. The radiographic appearance of tuberculosis in patients with the acquired immunodeficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 1985;131:393-396
36. Small PM, Hopewell PC, Schecter GF, Chaisson RE, Goodman PC Evolution of chest radiographs in treated patients with pulmonary tuberculosis and HIV infection. J Thorac Imaging 1995;9:74
37. Cauthen GM, Dooley SW, Onorato IM et al. Transmission of Mycobacterium tuberculosis from tuberculosis patients with HIV or AIDS. AmJ Epidemiol 1996;144:69-77
38. Kennedy DJ, Lewis WP, Barnes PF. Role of fiberoptic bronchoscopy in diagnosis of pulmonary tuberculosis in patients at risk for AIDS. Chest 1992;102:1040
39. Glassroth J. Diagnosis of tuberculosis. In: Tuberculosis: A Comprehensive International Approach. Reichman LB, Hershfield ES, Eds. New York: Marcel Dekker, Inc.: 1993:149-165
40. American Thoracic Society. Rapid diagnostic tests for tuberculosis. What is the appropriate use? Am J Respir Crit Care Med 1997;155:1804-1814
41. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-294
42. Parriens JH, St. Louis ME, Mukadi YB et al. Pulmonary tuberculosis in HIV infected patients in Zaire: A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995;332:779-784
43. Chaisson RE, Clermont HC, Holt EA et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without chemotherapy. Am J Respir Crit Care Med 1996;154:1034-1038
44. Iseman MDR: Is standard chemotherapy adequate in tuberculosis patients infected with the HIV? Am Rev Respir Dis 1987;136:1326
45. American Thoracic Society/Centers for Disease Control. Treatment and prevention of tuberculosis in adults and children. Am J Respir Crit Care Med 1994;149:1359-1374
46. Weis SE, Slocum PC, Blair FX et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-1184
47. World Health Organization, Global Tuberculosis Program. WHO Report on the Tuberculosis Epidemic. Geneva: World Health Organization; 1997
48. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug resistant tuberculosis in San Francisco, USA. Lancet 1996;348:928-931
49. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV infected patients. N Engl J Med 1995;332:336-337 Letter.
50. Peloquin CA. Antituberculosis drugs: Pharmacokinetics. In: Heifets LB, ed. Drug Susceptibility in the Chemotherapy of Mycobacterial Infection. Boca Raton: CRC Press; 1991:59-88
51. Bishai WR, Graham NMN, Harrington S et al. Brief report: Rifampin resistant tuberculosis in a patient receiving rifabutin prophylaxis. N Engl J Med 1996,334:1573-1575
52. Centers for Disease Control. Clinical update: Impact of HIV protease inhibitors on the treatment of HIV infected tuberculosis patients with rifampin. MMWR 1996;45:921-925
53. Englehard D, Stutman HR, Mark MI. Interaction of ketoconazole with rifampin and isoniazid. N EnglJ Med 1989;311:1681-1683
54. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990; 12:5327-5333
55. Kent JH. The epidemiology of multidrug-resistant tuberculosis in the United States. Med Clin North Am 1993;77:1391-1409
56. Coronado VG, Beck-Sague CM, Hutton MD et al. Transmission of multidrug resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection. Epidemiologic and restriction fragment length polymorphism analysis. J Infect Dis 1993;168:1052-1055
57. Frieden TR, Sherman LF, Man KL et al. A multi-institutional outbreak of highly drug-resistant tuberculosis. Epidemiology and clinical outcomes. JAMA 1996;276:1229-1235
58. Moss AR, Alland D, Telzak E et al. A city-wide outbreak of a multidrug-resistant strain of Mycobacterium tuberculosis in New York. Int J Tuberc Lung Dis 1997;1:115-121
59. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993,328:521-526
60. Kramer F, Modilevsky T, Waliany AR, Leedom JM, Barnes PF. Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Am J Med 1990;89:451-456
61. Nardell EA. Environmental control of tuberculosis Med Clin North Am 1993;77-1315-1334
62. Iseman MDR. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-791
63. Goble M, Iseman MDR, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-532
64. Telzak E, Sepkowitz K, Alpert P et al. Multidrug resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-911
65. Park MM, Davis AL, Schluger NW, Cohen H, Rom WM. Outcome of MDR-TB patients 1983-1993. Am J Respir Crit Care Med 1996;153:317-324
66. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272
67. Whalen CC, Johnson JL, Okwera A et al. Self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. N EnglJ Med In press
68. USPHS/IDSA. Prevention of opportunistic infection working group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations Clin Infect Dis 1995;21(suppl 1).S32-S43
69. Centers for Disease Control. Mycobacterium tuberculosis transmission in a health clinic-Florida. MMWR 1989;38:256
70. Dooley SW Jr, Castro KG, Hutton MD, Mullon RJ, Polder JA, Snider DE Jr. Guidelines for preventing transmission of tuberculosis in health care settings with special focus on HIV-related issues. MMWR 1990;39(RR-17):1-29
71. Centers for Disease Control. Guidelines for preventing the transmission of Mycobacterium tuberculosis in Healthcare facilities, 1995 MMWR 1994;43 (RR-13):1-132
72. Blumberg HM, Watkins DL, Berschling JD et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995;122:658-663
73. Hopewell PC. Factors influencing transmission and infectivity of Mycobacterium tuberculosis: Implications for clinical and public health management. In: Sande MA, Hudson LD, Root RK, eds. Respiratory Infections. New York: Churchill Livingstone: 1986:191-216
74. Wallis RS, Vjecha M, Amer Tahmosseb M et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): Enhanced cytokine expression and elevated beta 2 microglobulin in HIV-1-associated tuberculosis. J Infect Dis 1993;167:43-48
75. Lederman MM, Georges DL, Kusner DJ, Mudido P, Gaim CZ, Toossi Z. Mycobacterium tuberculosis and its purified protein derivitive activate expression of the human immunodeficiency virus. J Acquir Immune Defic Syndr 1994;7:727-733
76. Zhang Y, Doerfler M, Lel TC, Guillemia B, Rom WM. Mechanisms of stimulation of mterleukin 1β and tumor necrosis factor α by Mycobacterium tuberculosis components. J Clin Invest 1993;91:2076-2083
77. Wallis RS, Helfand MS, Whalen CC et al. Immune activation allergic drug toxicity and mortality in HIV positive tuberculosis. Tuberc Lung Dis 1996;77:516-523
78. Goletti D, Weissman D, Jackson RW et al. Effect of Mycobacterium tuberculosis on HIV replication: Role of immune activation. J Immunol 1996;157:1271-1278